Oxidative stress, associated with aging and
inflammation, is likely to play a role in the etiology of
prostate cancer. We evaluated potential associations between gene variants that result in reduced neutralization of
reactive oxygen species (ROS; MnSOD Ala-16Val, CAT -262 C>T, and GPX1 Pro200Leu) and
prostate cancer risk among 724 men with incident
prostate cancer who participated in the
Carotene and
Retinol Efficacy Trial (CARET) cohort, a randomized trial for the prevention of
lung cancer among men with a history of smoking and/or
asbestos exposure. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated by logistic regression. Nested case-control analyses included study participants with available
DNA (n = 533 cases and 1,470 controls), matched for race, age, and length of follow-time. Overall, there were no associations between genotypes of MnSOD, CAT, and GPX1 and
prostate cancer risk, although among men diagnosed before age 65, CAT TT genotype was associated with increased risk (OR, 2.0; 95% CI, 0.97-3.95). Further analyses stratified by factors related to environmental oxidative stress exposures did not modify associations. When calculating the number of risk alleles of MnSOD, CAT, and GPX1 hypothetically related to reduced protection against ROS, there was a nonsignificant relationship between
prostate cancer and carriage of five or more risk alleles, in comparison to men with less than five risk alleles (OR, 2.0; 95% CI, 0.90-4.42). In conclusion, it does not seem that variants in MnSOD, CAT, or GPX1 have an influence on
prostate cancer risk in this cohort of men who were smokers or exposed to
asbestos, although it is possible that cumulative defects in protection from oxidative stress may result in increased risk of the disease.